Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Diede Brunen"'
Autor:
Subarna Sinha, Daniel Thomas, Steven Chan, Yang Gao, Diede Brunen, Damoun Torabi, Andreas Reinisch, David Hernandez, Andy Chan, Erinn B. Rankin, Rene Bernards, Ravindra Majeti, David L. Dill
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
There are no robust methods for systematically identifying mutation-specific synthetic lethal (SL) partners in cancer. Here, the authors develop a computational algorithm that uses pan-cancer data to detect mutation-andcancer-specific SL partners and
Externí odkaz:
https://doaj.org/article/e49e620b8adf451f9e5a7aa02173d0b8
Autor:
Jorg van Loosdregt, Diede Brunen, Veerle Fleskens, Cornelieke E G M Pals, Eric W F Lam, Paul J Coffer
Publikováno v:
PLoS ONE, Vol 6, Iss 4, p e19047 (2011)
Maintenance of Foxp3 protein expression in regulatory T cells (Treg) is crucial for a balanced immune response. We have previously demonstrated that Foxp3 protein stability can be regulated through acetylation, however the specific mechanisms underly
Externí odkaz:
https://doaj.org/article/e5310b45f1a746f49c5370dcb0f464d9
Autor:
Ana Ruiz-Saenz, Chloe E. Atreya, Changjun Wang, Bo Pan, Courtney A. Dreyer, Diede Brunen, Anirudh Prahallad, Denise P. Muñoz, Dana J. Ramms, Valeria Burghi, Danislav S. Spassov, Eleanor Fewings, Yeonjoo C. Hwang, Cynthia Cowdrey, Christina Moelders, Cecilia Schwarzer, Denise M. Wolf, Byron Hann, Scott R. VandenBerg, Kevan Shokat, Mark M. Moasser, René Bernards, J. Silvio Gutkind, Laura J. van ‘t Veer, Jean-Philippe Coppé
Publikováno v:
Nature cancer, vol 4, iss 2
Nature Cancer, 4(2), 240-256. Nature Research
Nature Cancer, 4(2), 240-256. Nature Research
BRAFV600E mutation confers a poor prognosis in metastatic colorectal cancer (CRC) despite combinatorial targeted therapies based on the latest understanding of signaling circuitry. To identify parallel resistance mechanisms induced by BRAF–MEK–EG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6d9e001b5e77db572bc8303604ef49a
https://doi.org/10.1038/s43018-022-00508-5
https://doi.org/10.1038/s43018-022-00508-5
The x-axis depicts the average number of sequencing reads in the untreated/T0 samples. The y-axis depicts the log2 fold change in abundance of gRNAs in the untreated versus T0 population. gRNAs targeting essential genes are depicted in red, gRNAs tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::233e814cbb8531434f4d2080e821225f
https://doi.org/10.1158/1535-7163.22504482.v1
https://doi.org/10.1158/1535-7163.22504482.v1
Results from the CRISPR screen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0879837b67b3d6a38d410340581d55
https://doi.org/10.1158/1535-7163.22504464.v1
https://doi.org/10.1158/1535-7163.22504464.v1
(A-D) High PIM2 and -3 mRNA expression correlates with poor overall survival in neuroblastoma. Kaplan- Meier survival curves of the Versteeg cohort (88 patients) demonstrate overall patient survival, using median PIM expression as a cut-off value for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994a33f1b026856444820c82c18eaeb7
https://doi.org/10.1158/1535-7163.22504488
https://doi.org/10.1158/1535-7163.22504488
Patient characteristics of the neuroblastoma cohorts studied here.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cad9be506df05a7b00bfcdccceae4dab
https://doi.org/10.1158/1535-7163.22504470.v1
https://doi.org/10.1158/1535-7163.22504470.v1
(A-B) NF1 loss results in PIM inhibitor resistance in a colony formation assay. SK-N-SH cells were plated in 6-well plates and treated with increasing concentrations of AZD1208 or PIM-447. Drug-containing medium was refreshed every 3 days. Cells were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f7a78741bc5ce6a376a289821bdef56
https://doi.org/10.1158/1535-7163.22504479
https://doi.org/10.1158/1535-7163.22504479
(A-C) KELLY cells (1.106 cells) were subcutaneously implanted in NMRI mice. Once tumors were established (80mm3), animals were treated with vehicle or AZD1208 (90 mg/kg). Each line represents one tumor. (D) KELLY cells (5.106 cells) were subcutaneous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50d7aea967e439b0ec79d4224d29b6cd
https://doi.org/10.1158/1535-7163.22504473.v1
https://doi.org/10.1158/1535-7163.22504473.v1
The majority of high-risk neuroblastoma patients are refractory to, or relapse on, current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets. Here, we report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4169674cd2e411bedb7e5a141e588685
https://doi.org/10.1158/1535-7163.c.6537747
https://doi.org/10.1158/1535-7163.c.6537747